@article{oai:glim-re.repo.nii.ac.jp:00001702,
 author = {黒沢, 文人 and Kurosawa, Fumito},
 journal = {学習院大学大学院経済学研究科・経営学研究科研究論集, Research papers, Guraduate School of Economics and Management,Gakushuin University},
 month = {Oct},
 note = {application/pdf, In　some　economic　analyses，　productivity　ls　estimated　by　input　data　defined　by tangible　resources　such　as　labor　and　capital　stocks．　For　industrial　growth， however，　firms　need　not　only　tangible　resources　but　also　intangible　ones． 　　In　the　pharmaceutical　industry，　research　and　development（R＆D）investment　is acritical　expenditure　affecting　future　productivity．　The　future　return　to　R＆D investment　is　generated　by　future　inventions；in　other　words，　present　R＆D investment　provides　the　source　of　new　technology　and　new　products．　In　addition， new　products　and　new　technologies　require　accumulation　of　the　results　of　R＆D investment．　That　is　the　intangible　asset　called　knowledge　capital　stock． 　　In　this　paper，　I　estimate　marginal　capital　productivity　from　the　view　of　intan・ gible　capital　stocks．　I　found　that　the　marginal　capital　productivity　of　both tangible　capital　and　knowledge　capital　have　been　falling　steadily　over　a　number of　years．, 研究ノート(Note)},
 pages = {103--123},
 title = {製薬産業における限界資本生産性の計測と分析},
 volume = {7臨増},
 year = {1997},
 yomi = {クロサワ, フミト}
}